drugset / Trial / NCT07307768
Ketamine Biomarker Validation
RandomizedParallel-groupTriple-blindTreatment
Summary
We will be developing an EEG-based biomarker for the effects of ketamine infusion in patients with Depression. We will be analyzing the effects of ketamine infusion on Depression symptoms and EEG signals.
Timeline
- Start
- 2025-12-20
- Primary completion
- 2027-12-01
- Completion
- 2028-03-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ketamine | Small molecule | 0.25 mg/kg | — |
| Subject | Ketamine | Small molecule | 0.5 mg/kg | — |
| Subject | Ketamine | Small molecule | 0.75 mg/kg | — |
Indications
No indication recorded.